問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Colorectal Surgery

Division of General Surgery

Digestive System Department

China Medical University Hospital-Taipei (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

邱昌芳Chiu, Chang-Fang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

篩選

List

194Cases

2022-06-01 - 2029-01-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-11-30 - 2026-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-09-30 - 2026-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-12-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2023-08-01 - 2027-04-01

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2016-04-01 - 2018-12-31

Phase I

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
  • Condition/Disease

    Breast Cancer

  • Test Drug

    Oraxol

Participate Sites
6Sites

Terminated6Sites

趙大中
Taipei Veterans General Hospital

Division of Radiation Therapy

2017-09-01 - 2021-12-31

Phase I

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
  • Condition/Disease

    Breast Cancer

  • Test Drug

    Oraxol

Participate Sites
7Sites

Terminated6Sites

2017-04-27 - 2018-12-31

Phase I

A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
  • Condition/Disease

    Gastric Cancer/Esophageal Cancer/Gastro-esophageal Cancer

  • Test Drug

    Oraxol + Ramucirumab

Participate Sites
7Sites

Terminated6Sites

2013-03-01 - 2016-10-31

Phase III

A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPLATIN (mFOLFOX6) IN PATIENTS WITH METASTATIC HER2-NEGATIVE, MET-POSITIVE GASTROESOPHAGEAL CANCER
  • Condition/Disease

    METASTATIC HER2-NEGATIVE, MET-POSITIVE GASTROESOPHAGEAL CANCER

  • Test Drug

    ONARTUZUMAB (MetMAb)

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites